OncoMatch/Clinical Trials/NCT05803941
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Is NCT05803941 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies AAA617 for prostate cancer.
Treatment: AAA617 — The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Prior therapy
Must have received: (AAA617) — within an interventional, Phase I-IV Novartis sponsored clinical trial in prostate cancer
Must have received at least one dose of AAA617 within an interventional, Phase I-IV Novartis sponsored clinical trial in prostate cancer and have fulfilled the trial's requirements that allows them to participate in this study.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Arizona · Scottsdale, Arizona
- St. Joseph Hospital · Orange, California
- Providence Saint Johns Health Ctr · Santa Monica, California
- University of Colorado · Aurora, Colorado
- Hartford Hospital · Hartford, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify